Integrated kinetic studies and computational analysis on naphthyl chalcones as mushroom tyrosinase inhibitors.

S. Radhakrishnan,R. Shimmon,C. Conn,A. Baker

DOI: https://doi.org/10.1016/j.bmcl.2015.08.033

IF: 2.94

2015-10-01

Bioorganic & Medicinal Chemistry Letters

Abstract:

What problem does this paper attempt to address?

Neuro-Immuno-Psychological Aspects of Chronic Urticaria

Katarzyna Tomaszewska,Aleksandra Słodka,Bartłomiej Tarkowski,Anna Zalewska-Janowska

DOI: https://doi.org/10.3390/jcm12093134

2023-04-26

Abstract:Urticaria is a condition characterized by the development of itchy wheals (hives), angioedema, or both. The pathophysiology of chronic spontaneous urticaria (CSU) is still poorly understood. It is suggested that there is no dominant and independent mechanism of CSU; however, there are different immunological and non-immunological abnormalities that act simultaneously or/and follow each other resulting in clinical symptoms. The latest hypothesis points out that mast cells (MCs) to be activated via autoantibodies in autoallergic or autoimmune mechanism mediators released from degranulated MCs are responsible for the vasoactive and neurospecific effect in CSU. According to many clinical observations, it is suggested that psychological stress can be both a triggering factor in the onset of CSU and a modulating one in the course of the disease and therapy effectiveness. Of importance, the mechanistic background of the psychological stress response in the skin has not yet been fully elucidated. However, of note, a variety of inflammatory mediators, neuropeptides, and neurotransmitters facilitate this phenomenon. This review presents recent findings on the neuro-immuno-psychological aspects of CSU, highlighting an emerging role of neuro-immune interactions. It also points out the usefulness of psychological tools employment for the baseline diagnosis of perceived stress level and the presence of its symptoms. Furthermore, it proposes the implementation of non-invasive interventions to reduce psychological stress and anxiety. A bio-psycho-social approach including psychological support and patient education seems to be as important as traditional pharmacotherapy for CSU. It facilitates the effective control of active disease and a prolonged remission time in this disease.
Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management

Liting He,Wanyu Yi,Xin Huang,Hai Long,Qianjin Lu

DOI: https://doi.org/10.1007/s12016-021-08886-x

2021-09-16

Abstract:Chronic urticaria (CU) is a common skin condition characterized by the recurrence of wheals, with or without angioedema, which lasts for at least 6 weeks. Owing to its pruritus and incurability, this disease adversely affects the patients' physical and mental health and diminishes the quality of life. CU is generally classified into two subtypes based on the relevance of eliciting factors: chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), the latter of which is further divided into several subtypes. To improve the understanding and clinical management of this highly heterogeneous disorder, the EAACI/GA2LEN/EDF/WAO guideline was developed and published in 2018 based on evidence and expert consensus. The diagnostic and treatment algorithms proposed by the guideline have largely facilitated dermatologists in clinical practice. However, several questions remained unsolved and have been widely investigated in the recent years. First, a better understanding of the association between chronic urticaria and its potential underlying causes or eliciting factors such as autoimmunity, infections, coagulation aberrance, and vitamin D deficiency is warranted. This would lead to updates in the diagnostic and treatment procedures of different subtypes of chronic urticaria. Secondly, treatment for recalcitrant cases, especially those resistant to or intolerant of second-generation antihistamines and (or) omalizumab, calls for novel therapeutic measures or strategies. In the present review, we summarized recent advances in the understanding and management of both CSU and CIndU, with special emphasis on their underlying causes or eliciting factors, pathogenic mechanisms, potential targets for intervention, and advances in treatment strategies.

immunology,allergy
Diet and Chronic Urticaria: Dietary Modification as a Treatment Strategy

Joanna Jaros,Vivian Y Shi,Rajani Katta

DOI: https://doi.org/10.5826/dpc.1001a04

2019-12-31

Abstract:Patients with chronic urticaria (CU) often ask about dietary modification. Research has indicated that specific dietary changes may be helpful in a subset of patients. Immunological food reactions are rare, but potential triggers of CU include those seen in certain settings, as in patients with a history of tick bites, a history of raw or marinated fish ingestion, or those with celiac disease. Nonimmunological food intolerances may also contribute, although mechanism of action is not well understood. Trials of pseudoallergen-free diets and low-histamine diets have resulted in partial remission in a subset of patients, while oral provocation testing has confirmed that some patients experience worsening of symptoms after ingestion of food additives, tomatoes, herbs, seafood, alcohol, and other foods. An increased prevalence of vitamin D deficiency has also been noted in patients with CU compared with healthy controls. While oral antihistamines remain the mainstay of therapy in CU, education on potential dietary factors may be offered to a selection of the group of patients. For those at risk or reporting symptoms suggestive of celiac disease, vitamin D deficiency, delayed reactions to mammalian meat, or exposure to raw fish, further workup is recommended. While education on dietary modification may be offered to other patients, this approach may benefit only a subset, and no test is available to identify these patients. A minimum of 3 weeks may be needed to determine response, and only specific diets that have been systematically studied should be considered. Any elimination diet should be used with caution because of the potential for nutritional deficiencies.
Therapies for Chronic Spontaneous Urticaria: Present and Future Developments

Riccardo Asero,Paolo Calzari,Silvia Vaienti,Massimo Cugno

DOI: https://doi.org/10.3390/ph17111499

IF: 4.6

2024-11-08

Pharmaceuticals

Abstract:Chronic spontaneous urticaria (CSU) is a complex dermatological condition characterized by recurrent wheals and/or angioedema lasting for more than six weeks, significantly impairing patients' quality of life. According to European guidelines, the first step in treatment involves second-generation H1-antihistamines (sgAHs), which block peripheral H1 receptors to alleviate symptoms. In cases with inadequate responses, the dose of antihistamines can be increased by up to fourfold. If symptoms persist despite this adjustment, the next step involves the use of omalizumab, a monoclonal anti-IgE antibody, which has shown efficacy in the majority of cases. However, a subset of patients remains refractory, necessitating alternative treatments such as immunosuppressive agents like cyclosporine or azathioprine. To address these unmet needs, several new therapeutic targets are being explored. Among them, significant attention is being given to drugs that block Bruton's tyrosine kinase (BTK), such as remibrutinib, which reduces mast cell activation. Therapies like dupilumab, which target the interleukin-4 (IL-4) and IL-13 pathways, are also under investigation. Additionally, molecules targeting the Mas-related G protein-coupled receptor X2 (MRGPRX2), and those inhibiting the tyrosine kinase receptor Kit, such as barzolvolimab, show promise in clinical studies. These emerging treatments offer new options for patients with difficult-to-treat CSU and have the potential to modify the natural course of the disease by targeting key immune pathways, helping to achieve longer-term remission. Further research is essential to better elucidate the pathophysiology of CSU and optimize treatment protocols to achieve long-term benefits in managing this condition. Altogether, the future of CSU treatments that target pathogenetic mechanisms seems promising.

pharmacology & pharmacy,chemistry, medicinal
A Practical Approach to Diagnosing and Managing Chronic Spontaneous Urticaria

Adam Friedman,Shawn G. Kwatra,Gil Yosipovitch

DOI: https://doi.org/10.1007/s13555-024-01173-5

2024-05-19

Dermatology and Therapy

Abstract:Chronic spontaneous urticaria (CSU) is an unpredictable inflammatory skin condition characterized by the spontaneous onset of itchy wheals, angioedema, or both, which occurs for longer than 6 weeks overall. Despite the relatively straightforward diagnostic algorithm for CSU, relying primarily on a detailed medical history and only limited laboratory tests, patients often wait years to be diagnosed, with many cycling through different healthcare practitioners before a diagnosis is made. Even then, current treatment options for CSU are limited, with approximately half of patients resistant to standard-of-care second-generation antihistamines at standard or higher doses. As such, there is an unmet need for improved, streamlined management for patients with CSU. Here, we review the evidence-based diagnostic algorithm for CSU, consider the required steps of the diagnostic workup, and provide practical, real-world advice on the management of CSU to improve the timely diagnosis and care of patients with this debilitating disease.

dermatology
Humanistic Burden of Refractory and Nonrefractory Chronic Idiopathic Urticaria: A Real-world Study in the United States

Ben Hoskin,Benjamin Ortiz,Brandee Paknis,Abhishek Kavati

DOI: https://doi.org/10.1016/j.clinthera.2018.12.004

Abstract:Purpose: Chronic idiopathic urticaria (CIU) is a debilitating skin condition that can profoundly affect patients' quality of life. This study explored the impact of refractory and nonrefractory CIU on patients in the real-world setting in the United States. Methods: Data were collected from the Adelphi Real World 2015 Urticaria Disease-Specific Programme. Physicians completed patient record forms (PRFs) for 4 consecutive patients consulting with nonrefractory CIU and 6 patients with refractory CIU. The PRF included information on patient characteristics, medication, and disease severity; physicians were asked about the impact of CIU on patients, and to rate their satisfaction with patients' treatment (scale, 1-7 [1 = extremely dissatisfied and 7 = extremely satisfied]). The same patients were asked to complete a patient self-completion form (PSC). This included questions regarding how CIU affected their everyday life and their satisfaction with and understanding of their condition and medications. The PSC included a number of patient-reported outcomes measures: the Dermatology Life Quality Index (scored from 0 to 30, with higher scores indicating greater impact), the Work Productivity and Activity Impairment (4 scores calculated [absenteeism, presenteeism, work productivity loss, and activity impairment], each scored from 0% to 100% after transformation, with higher scores indicating greater impairment), and the Jenkins Sleep Scale (assessed over 30 days; scored from 0 to 20, with higher scores indicating greater sleep disturbance). Completion of the PSC was voluntary. Findings: Seventeen physicians completed a total of 184 PRFs (108 for patients with refractory CIU; 76 for those with nonrefractory CIU); 140 of these 184 patients completed a PSC form (93 with refractory CIU; 47 with nonrefractory CIU). Overall, 26% of the entire population (30% of patients with refractory CIU and 17% with nonrefractory CIU) reported that skin symptoms had a great effect on their lives (Dermatology Life Quality Index score ≥11). Sleep problems were common: mean Jenkins Sleep Scale scores were 7.8 overall (8.1 for patients with refractory CIU and 7.2 for those with nonrefractory CIU). Overall work impairment was 19% in the overall population, with similar values in refractory and nonrefractory patients (18% and 20%, respectively). Physician satisfaction with disease control was not high, with physicians reporting a mean score of 4.8 on a 7-point scale. Twenty-one percent of patients were extremely dissatisfied, very dissatisfied, or dissatisfied with their treatment, and 52% believed better control could be achieved. Implications: The humanistic burden of CIU is high. There is clearly a need for better management of CIU to improve outcomes for patients.
A Communication Method for Wireless Mesh Networks Suitable to IoT Communication Environment

Kyohei Kishi,Hiroyuki Suzuki,A. Koyama

DOI: https://doi.org/10.1007/978-3-319-61566-0_11

2017-07-10

Abstract:
Impact of Chronic Spontaneous or Inducible Urticaria on Occupational Activity

Amandine Baudy,Nadia Raison-Peyron,Chris Serrand,Marie-Noëlle Crépy,Aurélie Du-Thanh

DOI: https://doi.org/10.2340/actadv.v104.36122

2024-03-29

Abstract:The impact of chronic urticaria on work has been scarcely reported, whereas its peak incidence is between the ages of 20 and 40. The aim of this study was to assess the occupational impact of chronic urticaria and its treatment, by combining objective and patient-reported data. A monocentric observational study was performed using questionnaires over a 1-year period from 2021 to 2022 in chronic urticaria patients who were in a period of professional activity and agreed to participate. Of the 88 patients included, 55.7% assessed the occupational impact of their chronic urticaria as significant, and even more severe when chronic urticaria was poorly controlled. Some 86% of patients had symptoms at work, in a third of cases aggravated by work. However, occupational physical factors were not associated with an aggravation of inducible chronic urticaria. A total of 20% reported treatment-related adverse effects affecting their work. Despite low absenteeism, presenteeism and reduced productivity were important (> 20%). Six patients (6.8%) had difficulties keeping their work. For 72.7% of the patients, the occupational physician was not informed. The occupational impact of chronic urticaria should be discussed during consultations, particularly when it is insufficiently controlled. The occupational physician should be informed in order to support patients’ professional project.

dermatology
Emerging treatments for chronic urticaria

Bettina Wedi

DOI: https://doi.org/10.1080/13543784.2022.2042513

2022-02-18

Expert Opinion on Investigational Drugs

Abstract:INTRODUCTION: Across the globe, chronic urticaria (CU), i.e. chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CINDU), is common, long-persisting and difficult to manage. Still, at least one-fifth is not sufficiently controlled by guideline-recommended treatment with H1-antihistamines and add-on therapy with the anti-IgE monoclonal antibody omalizumab.AREAS COVERED: Using PubMed, ClinicalTrials.gov, Congress websites, and websites of the manufacturers, this review explored the pipeline, namely anti-IgE-, anti-cytokine-, anti-receptor biologics, and small molecules, in clinical development for CU.EXPERT OPINION: The CU pipeline is promising. While three omalizumab biosimilars are investigated, the assumed early approval of ligelizumab will expand the effective and safe anti-IgE approach observed with omalizumab. For other anti-IgEs like UB-221, the development is behind. Data are too limited so far to clearly define the role of anti-cytokine and anti-cytokine receptor biologics such as dupilumab, tezepelumab, mepolizumab, benralizumab, and CDX-0159, of which only dupilumab is actually investigated in phase 3. Among three selective oral BTK inhibitors, remibrutinib, rilzabrutinib, and fenebrutinib, the development of remibrutinib is most advanced (phase 3). As the pipeline addresses different targets, study results will give deeper insights into the pathomechanisms of CU. Hopefully, in the next future additional approved and also more targeted approaches will be available.

pharmacology & pharmacy
Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment

Torsten Zuberbier,Luis Felipe Ensina,Ana Giménez-Arnau,Clive Grattan,Emek Kocatürk,Kanokvalai Kulthanan,Pavel Kolkhir,Marcus Maurer

DOI: https://doi.org/10.1016/s0140-6736(24)00852-3

IF: 202.731

2024-07-13

The Lancet

Abstract:Summary Chronic urticaria is a common and debilitating mast cell-driven skin disease presenting with itchy wheals, angio-oedema, or both. Chronic urticaria is classified as spontaneous (without definite triggers) and inducible (with definite and subtype-specific triggers; eg, cold or pressure). Current management guidelines recommend step-up administration of second-generation H1-antihistamines to four-fold the approved dose, followed by omalizumab and ciclosporin. However, in many patients, chronic urticaria does not respond to this linear approach due to heterogeneous underlying mechanisms. A personalised endotype-based approach is emerging based on the identification of autoantibodies and other drivers of urticaria pathogenesis. Over the past decade, clinical trials have presented promising options for targeted treatment of chronic urticaria with the potential for disease modification, including Bruton's tyrosine kinase inhibitors, anti-cytokine therapies, and mast cell depletion. This Therapeutics article focuses on the evidence for these novel drugs and their role in addressing an unmet need for personalised management of patients with chronic urticaria.

medicine, general & internal
Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances

Allen Kaplan,Mark Lebwohl,Ana M. Giménez‐Arnau,Michihiro Hide,April W. Armstrong,Marcus Maurer

DOI: https://doi.org/10.1111/all.15603

2022-12-01

Allergy: European Journal of Allergy and Clinical Immunology

Abstract:Chronic spontaneous urticaria (CSU) is a debilitating skin disease characterized by intensely itchy wheals, angioedema, or both. Symptoms recur spontaneously, on a near‐daily basis, over >6 weeks; many patients experience flare‐ups over several years and, consequently, a reduced quality of life. Differences between the inflammatory profiles of the skin of CSU patients (wheals and non‐lesional sites) and healthy controls indicate that key drivers such as mast cells, eosinophils, and basophils interact, release vasoactive mediators, and prime the skin, leaving patients predisposed to symptoms. Many cytokines and chemokines involved in these inflammatory networks and their corresponding intracellular signaling cascades have been identified. These insights informed the development of therapies such as omalizumab, dupilumab and BTK inhibitors, marking a renewed focus on pathogenesis in CSU clinical research. Despite progress, current therapies provide symptomatic control but do not appear to redress the inflammatory balance in the skin permanently. A deeper understanding of CSU pathogenesis will permit a more targeted approach to developing novel treatments with curative intent. Here, we review what is known about the pathogenesis of CSU and consider how this can be used to identify rational targets to improve patient care further.
Fluconazole for the treatment of Cryptococcus neoformans meningitis in an immunocompetent host.

A. Mansour,Y. Sultan,Isabelle A. Nakhla,Mosaad Morsy,R. Frenck

2003-04-01

Neurosciences

Abstract:We present a case of a 23-year-old immunocompetent male who presented with chronic meningitis and was diagnosed as cryptococcal meningitis by positive cryptococcal antigen titer. The cerebrospinal fluid culture was positive for Cryptococcus neoformans. He was treated initially with amphotericin B but was later changed to fluconazole due to toxicity. This case highlights the use of fluconazole to successfully treat chronic meningitis in an immunocompetent host.
Prevalence and phenotypic features of chronic spontaneous urticaria

A.J. Batyrbaeva,J.B. Ispayeva,D.S. Fomina

DOI: https://doi.org/10.53511/pharmkaz.2024.53.40.005

2024-09-26

Farmaciâ Kazahstana

Abstract:In recent years, there has been a steady increase in the incidence of urticaria. It is believed that the etiology of urticaria is a heterogeneous disease. Chronic urticaria (HU) subtypes have common clinical manifestations but may differ phenotypically. The article describes the epidemiology, features of the phenotypes of chronic spontaneous urticaria, their diagnosis, and treatment. New data show that the prevalence of CSU is geographically heterogeneous, high in all age groups, and growing. Significant progress has been made in the study of two main autoimmune mechanisms that determine the pathogenesis of CSU. Autoimmune (autoallergic) type I CSU is associated with IgE antibodies against autoantigens, for example, thyroid peroxidase of the thyroid gland and IL-24. Autoimmune CSU type IIb is mediated by autoantibodies that activate mast cells, for example, through IgE and FcεRI, and is present in less than 10% of patients with CSU. These two types of autoimmune hypersensitivity, i.e., autoimmunity type I (also called autoallergy) and autoimmunity type IIb, are hypothesized to be the underlying mechanisms in most patients with CSU. The goal of treatment for CSU is to achieve complete control of the disease with the absence of signs and symptoms and normalization of quality of life, but the course of the disease varies significantly in response to therapy and the timing of its development. The problem of the prevalence of CSU is highly relevant; clinical and scientific information on this problem is constantly being updated. Therefore, increasing alertness to this problem among doctors of all specialties is necessary. This review aims to provide physicians treating patients with CSU with updated information on the types, prevalence, diagnostic methods of examination, and features of treatment for CSU.
Chronic spontaneous urticaria: diagnosis, treatment, and management

Jesse S. Kogelman

DOI: https://doi.org/10.1097/jdpa.0000000000000026

2024-07-17

Abstract:Chronic spontaneous urticaria (CSU) is a disabling condition in which recurrent wheals, with or without angioedema, occur for over 6 weeks. CSU occurs in up to 1% of the general population at any time and, on average, lasts 2–5 years in duration. Standard therapy for CSU includes second-generation antihistamines and omalizumab. However, 25%–50% of patients are refractory to these treatments. CSU profoundly impairs patients’ quality of life and has a substantial societal impact, including significant health care costs and decreased work productivity. These factors underscore the importance of health care providers to be familiar with the diagnosis and management of this condition. This article reviews the epidemiology, pathogenesis, aggravating factors, clinical manifestations, diagnostic assessment, and treatment of CSU.
Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020

Marcus Maurer,Kilian Eyerich,Stefanie Eyerich,Marta Ferrer,Jan Gutermuth,Karin Hartmann,Thilo Jakob,Alexander Kapp,Pavel Kolkhir,Désirée Larenas-Linnemann,Hae-Sim Park,Gunnar Pejler,Mario Sánchez-Borges,Knut Schäkel,Dagmar Simon,Hans-Uwe Simon,Karsten Weller,Torsten Zuberbier,Martin Metz

DOI: https://doi.org/10.1159/000507218

2020-01-01

International Archives of Allergy and Immunology

Abstract:This update on chronic urticaria (CU) focuses on the prevalence and pathogenesis of chronic spontaneous urticaria (CSU), the expanding spectrum of patient-reported outcome measures (PROMs) for assessing CU disease activity, impact, and control, as well as future treatment options for CU. This update is needed, as several recently reported findings have led to significant advances in these areas. Some of these key discoveries were first presented at past meetings of the Collegium Internationale Allergologicum (CIA). New evidence shows that the prevalence of CSU is geographically heterogeneous, high in all age groups, and increasing. Several recent reports have helped to better characterize two endotypes of CSU: type I autoimmune (or autoallergic) CSU, driven by IgE to autoallergens, and type IIb autoimmune CSU, which is due to mast cell (MC)-targeted autoantibodies. The aim of treatment in CU is complete disease control with absence of signs and symptoms as well as normalization of quality of life (QoL). This is best monitored by the use of an expanding set of PROMs, to which the Angioedema Control Test, the Cholinergic Urticaria Quality of Life Questionnaire, and the Cholinergic Urticaria Activity Score have recently been added. Current treatment approaches for CU under development include drugs that inhibit the effects of signals that drive MC activation and accumulation, drugs that inhibit intracellular pathways of MC activation and degranulation, and drugs that silence MCs by binding to inhibitory receptors. The understanding, knowledge, and management of CU are rapidly increasing. The aim of this review is to provide physicians who treat CU patients with an update on where we stand and where we will go. Many questions and unmet needs remain to be addressed, such as the development of routine diagnostic tests for type I and type IIb autoimmune CSU, the global dissemination and consistent use of PROMs to assess disease activity, impact, and control, and the development of more effective and well-tolerated long-term treatments for all forms of CU.<br/>Int Arch Allergy Immunol

immunology,allergy
Current insights on gut microbiome and chronic urticaria: progress in the pathogenesis and opportunities for novel therapeutic approaches

Rui Cai,Changhan Zhou,Ruisi Tang,Yuanling Meng,Jumei Zeng,Yuqing Li,Xiang Wen

DOI: https://doi.org/10.1080/19490976.2024.2382774

IF: 12.2

Gut Microbes

Abstract:Chronic urticaria (CU) is a prevalent skin disorder greatly impacting the patients' life quality, in which immune dysregulation mediated by gut microbiome plays a significant role. Several studies have found the gut dysbiosis exists in patients with CU. In addition, infection may also be one of the causes of CU. The primary treatment currently used for CU is the second-generation non-sedating H1-antihistamines (nsAH). However, there are some limitations in current therapies. Based on the latest evidence, this review provides an updated overview of how the gut dysbiosis influences CU development, explores potential therapeutic approaches based on the gut microbiota and summarizes the interaction between gut microbiota and current treatment.
Evaluation of guidelines line-care approach to the treatment of chronic inducible urticaria.

J. Sánchez,D. Caraballo,D. Amaya

DOI: https://doi.org/10.1016/j.jaip.2024.05.011

IF: 11.022

2024-05-18

The Journal of Allergy and Clinical Immunology In Practice

Abstract:Background Chronic Inducible Urticaria (CIndU) management often follows Chronic Spontaneous Urticaria (CSU) guidelines, but a step-by-step evaluation of their effectiveness in CIndU is lacking. Objective To assess the clinical impact of adapting CSU international guidelines for CIndU management. Methods We conducted a prospective cohort study involving patients diagnosed with CIndU based on challenge tests and a Urticaria Control Test (UCT) score of < 11 points. Following the guidelines, a stepwise approach was used: avoidance measures, antihistamines, omalizumab, and cyclosporine. Treatment steps were added based on individual response, with control defined as UCT > 12 points. Pharmacological steps were evaluated for at least one month, with the next step initiated in case of a UCT score < 11 points Results We enrolled 194 patients with CIndU. One hundred and thirty-four patients had CIndU with concomitant CSU and 60 had CIndU only. Following the step-by-step approach outlined in the guidelines, a total of 159 (81.9%) patients reaches a UCT > 12 points; With avoidance measures 23 (11.8%) patients; antihistamines 84 (43.2%); omalizumab 35 (18%); and with cyclosporine 17 (8.7%). Conclusions This study supports the use of a stepwise approach based on CSU guidelines for CIndU management. However, a significant proportion of patients, particularly those with CIndU only, did not achieve adequate control. This highlights the heterogeneity within CIndU and the need for further research to develop new therapies for CIndU patients who remain uncontrolled.

immunology,allergy
Local hyperalimentation of open wounds

J. Viljanto,J. Raekallio

DOI: https://doi.org/10.1002/bjs.1800630603

1976-06-01

Abstract:After débridement of necrotized and devitalized tissue in deep burns and large traumatic soft tissue defects, the raw surfaces were covered with separate sheets of viscose cellulose sponge (VCS), each moistened by continuous slow infusion of one of the following solutions: (a) 0 9 per cent NaCI; (b) 10 per cent glucose; (c) Rheomacrodex (dextrane hydrolysate in 0.9 per cent NaCl); (d) 7 per cent Levamin a mixture of essential amino acids and glycin in 5 per cent sorbitol; (e) a combination of two solutions containing amino acids (Le‐7402 A) and glucose, electrolytes and vitamins (Le‐7402 B). The ceilulose sponges were removed or changed 3–7 days later. Macroscopically, histologically and enzyme histochemically, the most active granulation tissue formation was found under the VCS moistened with amino acid solutions, especially when accompanied by glucose and vitamin supplementation. The results strongly suggest that local cellular hyperalimentation of open raw wound surfaces is possible, permitting a new kind of nutritional support in these patients.
Determination of phosphodiesterase-5 inhibitors and analogs using high-performance liquid chromatography with ultraviolet detection.

Elisa A Nickum,C. Flurer

DOI: https://doi.org/10.1093/chromsci/bmu010

Journal of Chromatographic Science

Abstract:A considerable number of erectile dysfunction products, and dietary supplements suspected of containing phosphodiesterase-5 (PDE-5) inhibitors, have been analyzed by the US Food and Drug Administration. Often these samples are found to contain the approved active pharmaceutical ingredients (APIs) such as sildenafil, tadalafil or vardenafil. However, analogs of these APIs have also been identified in many samples and products containing multiple PDE-5 inhibitors have also been found. A single high-performance liquid chromatography with ultraviolet detection method has been developed for the determination of sildenafil, tadalafil, vardenafil and a number of commonly encountered analogs in pharmaceutical dosage forms and dietary supplement products, including tablets, capsules, bulk powders, troches and liquids. This method was designed as an alternative to methods developed for the determination of a single PDE-5 inhibitor. Using this protocol, 14 PDE-5 inhibitor compounds can be separated and determined in a single analysis.
Cost and Cost-Effectiveness of the Management Strategies of Chronic Urticaria: A Systematic Review

Surapon Nochaiwong,Mati Chuamanochan,Chidchanok Ruengorn,Ratanaporn Awiphan,Jonathan A Bernstein,Kednapa Thavorn

DOI: https://doi.org/10.1001/jamadermatol.2024.2863

2024-08-28

Abstract:Importance: Although treatment for chronic urticaria (CU) has improved over the past decades, evidence regarding costs and net benefits associated with these treatment strategies have yet to be comprehensively characterized and synthesized. Objective: To summarize the cost and cost-effectiveness of CU management strategies. Evidence review: An extensive systematic literature search of 6 databases (MEDLINE, Embase, PubMed Cochrane, Scopus, and CINAHL) and gray literature sources, without language restriction, was conducted and updated to March 23, 2024. Articles that performed cost analysis or full economic evaluation among patients with CU were included. Two reviewers independently extracted data, such as annual costs of health care services or incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY). All monetary values were converted and inflated to 2023 US dollars. Evidence-based synthesis for health benefit was judged using the Evidence Rating Matrix by the Institute for Clinical and Economic Review. Findings: Seventeen unique studies (11 cost analysis studies and 6 full economic evaluations) were included. With the wide variation in health care resources, services that included biologic omalizumab utilization had higher annual health care cost estimations for CU management than services that did not include omalizumab prescription (median [IQR] cost, $6933 [$5988-$8717] vs $5621 [$2488-$8754]). The biologic omalizumab, 300 mg, for H1 antihistamine-refractory chronic spontaneous urticaria (CSU) (3 studies) was found to have a median (IQR) ICER of $89 005 ($36 058-$145 694) per QALY (evidence rating as incremental or better; moderate certainty with substantial net health benefit). Routine laboratory testing among patients with CSU with otherwise normal histories and physical examination findings (1 study) had ICERs ranging from $1 427 928 to $1 950 524 per QALY (evidence rating as comparable or inferior; moderate certainty that the net health benefit is inferior). Conclusions and relevance: With limited evidence of cost-effectiveness, biologic omalizumab, 300 mg, for H1 antihistamine-refractory CSU was found to be cost-effective in US health care services at the willingness to pay threshold of $150 000 per QALY. Meanwhile, routine laboratory testing among patients with CSU without compelling indication was not cost-effective. Future studies in more diverse CU populations and resource settings are needed to fill evidence gaps.

Integrated kinetic studies and computational analysis on naphthyl chalcones as mushroom tyrosinase inhibitors.

Neuro-Immuno-Psychological Aspects of Chronic Urticaria

Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management

Diet and Chronic Urticaria: Dietary Modification as a Treatment Strategy

Therapies for Chronic Spontaneous Urticaria: Present and Future Developments

A Practical Approach to Diagnosing and Managing Chronic Spontaneous Urticaria

Humanistic Burden of Refractory and Nonrefractory Chronic Idiopathic Urticaria: A Real-world Study in the United States

A Communication Method for Wireless Mesh Networks Suitable to IoT Communication Environment

Impact of Chronic Spontaneous or Inducible Urticaria on Occupational Activity

Emerging treatments for chronic urticaria

Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment

Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances

Fluconazole for the treatment of Cryptococcus neoformans meningitis in an immunocompetent host.

Prevalence and phenotypic features of chronic spontaneous urticaria

Chronic spontaneous urticaria: diagnosis, treatment, and management

Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020

Current insights on gut microbiome and chronic urticaria: progress in the pathogenesis and opportunities for novel therapeutic approaches

Evaluation of guidelines line-care approach to the treatment of chronic inducible urticaria.

Local hyperalimentation of open wounds

Determination of phosphodiesterase-5 inhibitors and analogs using high-performance liquid chromatography with ultraviolet detection.

Cost and Cost-Effectiveness of the Management Strategies of Chronic Urticaria: A Systematic Review